Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Penn Medicine (University of Pennsylvania)

Sites in Philadelphia, PA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1360
Shown on this page
12
Current sort
Recently updated
Campus scope
Penn Medicine (University of Pennsylvania), Philadelphia, PA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Penn Medicine (University of Pennsylvania), Philadelphia, PA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 229–240 of 1,360 matching trials with a site at Penn Medicine (University of Pennsylvania), Philadelphia, PA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

NCT07100106
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer
Interventions
GDC-4198, Giredestrant, Abemaciclib
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
32
States / cities
Huntsville, Alabama • Tucson, Arizona • Duarte, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 2:53 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

NCT03887455
Site status not listed — check the official record
View directory record Official record
Conditions
Early Alzheimer's Disease
Interventions
Lecanemab IV, Placebo, Lecanemab SC
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years to 90 Years
Enrollment
1,906 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
112
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 2:53 PM EDT
Recruiting Phase 3 Interventional

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

NCT06377852
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib 125mg, Ribociclib 600mg, Ribociclib, Palbociclib
Drug
Lead sponsor
American Society of Clinical Oncology
Other
Eligibility
60 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
88
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 2:53 PM EDT
Recruiting Not applicable Interventional

MOVE-HF MOtivating Physical Activity With BehaVioral Economics in Heart Failure With Preserved Ejection Fraction

NCT06670001
Status at this site: Recruiting
View directory record Official record
Conditions
HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Gamification plus social incentive, Gamification plus competition
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 2:53 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

NCT07174310
Status at this site: Recruiting
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Prasinezumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 85 Years
Enrollment
900 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fullerton, California + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 2:53 PM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

NCT05923866
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple System Atrophy (MSA)
Interventions
ONO-2808, Placebo
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
30 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
30
States / cities
Fountain Valley, California • Los Angeles, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 2:53 PM EDT
Active, not recruiting Phase 3 Interventional

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

NCT04273945
Site status not listed — check the official record
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
43
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 22, 2026, 2:53 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy

NCT07210723
Status at this site: Recruiting
View directory record Official record
Conditions
Symptomatic Genetic Dilated Cardiomyopathy
Interventions
danicamtiv, Placebo
Drug
Lead sponsor
Kardigan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 2:53 PM EDT
Active, not recruiting Phase 2 Interventional

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

NCT04929028
Site status not listed — check the official record
View directory record Official record
Conditions
AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma, Anal Squamous Cell Carcinoma, HIV Infection, Rectal Squamous Cell Carcinoma, Stage II Rectal Cancer AJCC v8, Stage IIB Anal Cancer AJCC v8, Stage III Anal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8
Interventions
Anoscopy, Biospecimen Collection, Capecitabine, Colonoscopy, Computed Tomography, Digital Rectal Examination, Echocardiography Test, Fludeoxyglucose F-18, Fluorouracil, Intensity-Modulated Radiation Therapy, Lymph Node Biopsy, Magnetic Resonance Imaging, Mitomycin, Nivolumab, Positron Emission Tomography, Proctoscopy, Questionnaire Administration, Sigmoidoscopy
Procedure · Drug · Other + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2031
U.S. locations
14
States / cities
San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 2:53 PM EDT
Active, not recruiting No phase listed Observational

Effects of Immune Checkpoint Inhibitors on Coronary Microvasculature

NCT06332131
Site status not listed — check the official record
View directory record Official record
Conditions
Coronary Microvascular Dysfunction, Cardiotoxicity, Breast Cancer, Lung Cancer (NSCLC)
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 2:53 PM EDT
Active, not recruiting No phase listed Observational

Cardiotoxicity in Locally Advanced Lung Cancer Patients Treated With Chemoradiation Therapy

NCT04305613
Site status not listed — check the official record
View directory record Official record
Conditions
Cardiotoxicity, Lung Cancer Stage III, Lung Cancer Stage II, Radiation Toxicity
Interventions
Chemoradiation
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
8
States / cities
Birmingham, Alabama • Boston, Massachusetts • St Louis, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 2:53 PM EDT
Recruiting No phase listed Observational

Autoimmunity After Checkpoint Blockade

NCT04119713
Status at this site: Recruiting
View directory record Official record
Conditions
Autoimmunity, Cancer, Immunotoxicity, Oncology
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 2:53 PM EDT

About this Penn Medicine (University of Pennsylvania) institution page

What this page lists
ClinicalTrials.gov records that list Penn Medicine (University of Pennsylvania) in Philadelphia, PA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by University of Pennsylvania at any site, browse by condition, or browse by U.S. city.